RxDoctor Payments Data

Hazel King, NP

Nurse Practitioner · Puyallup, WANPI 1558905356

Payments from drug & device makers

$1,532in general payments, 2019–2025

Across 52 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$243
  • Nalu Medical, Inc.$242
  • AbbVie$210
  • Avanir Pharmaceuticals, Inc.$86
  • Urovant Sciences Inc$82
  • AstraZeneca$81
  • plus $589 from 17 others

What the payments were for

  • Food & beverage$1,532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,532 in reported general payments places this provider in the 90th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$121,764
Medicare patients
190
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$11,052
JanuviaSitagliptin Phosphate12$3,374
MyrbetriqMirabegron13$3,369
XareltoRivaroxaban11$3,059
Potassium Chloride62$2,044
Gabapentin134$1,436
Atorvastatin Calcium121$1,324
Famotidine18$1,197
Divalproex Sodium34$1,074
Montelukast Sodium51$952
Levothyroxine Sodium88$880
Levetiracetam31$664
Olanzapine13$543
Losartan Potassium56$531
Amlodipine Besylate64$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$11,05241 claims
Johnson & JohnsonXarelto$36$3,05911 claims
Lilly USA, LLCOlanzapine$15$54313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Puyallup

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →